OptiBiotix Health PLC Launch of weight management products (6922B)
12 October 2020 - 5:00PM
UK Regulatory
TIDMOPTI
RNS Number : 6922B
OptiBiotix Health PLC
12 October 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Launch of weight management products in Australia and New
Zealand
Shakes and bars containing OptiBiome(R) technology
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, announces the launch of meal
replacement shakes and bars containing OptiBiotix's OptiBiome(R)
proprietary weight management technology under the Optislim(R)
brand with Woolworths, ChemistWarehouse and on OptiPharm Pty Ltd's
("OptiPharm") online store in Australia and New Zealand.
These simultaneous launches build on a licence agreement entered
into in March 2020 grant ing OptiPharm exclusive use of the
OptiBiome(R) trademark in Australia, parts of Asia, New Zealand,
Middle East, the Gulf States and North America (RNS: 31 March 2020)
and subsequent extension of terms to include Europe (RNS: 5 August
2020).
OptiPharm is a privately owned Australian company which has been
operating for 24 years. OptiPharm's flagship brand , Optislim(R) ,
is the No. 1 Australian weight management brand incorporating
shakes, soups and bars available as total (very low calorie diet)
or partial (low calorie diet) meal replacements.
Garry McDonald, Managing Director of OptiPharm, commented: "We
are delighted to announce the release of our Optislim (R) -
Optibiome (R) range of meal replacement shakes & snack bars.
Products will be available to Australian consumers from the week
commencing 12 October 2020 via the Chemist Warehouse group and the
Woolworths supermarket chain. Release will follow shortly
throughout New Zealand with contracts currently being finalised for
a number of regions throughout Asia. Essentially, we are
revolutionising meal replacements utilising OptiBiome(R), the award
winning, patented ingredient from OptiBiotix. We look forward to a
long and successful association with the OptiBiotix team."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division , c o mmented: "We are very pleased to announce the
commercial launch of these weight management products containing
OptiBiome(R) under OptiPharm's Optislim (R) brand. OptiBiotix's
partnership with Australia's No. 1 weight management brand combined
with the retailers' distribution network allows the Company to
access a wide base of customers in Australia and New Zealand and
provide them with a scientifically proven and award-winning
ingredient to help them achieve their weight loss. This first
commercial step with OptiPharm highlights the strength of the
relationship between the two companies and we look forward to
future commercial launches beyond Australia and New Zealand."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements, and health snacks and food products. The Company's
current areas of focus include obesity, digestive health,
cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding OptiBiotix's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PRLFLFFEILLAIII
(END) Dow Jones Newswires
October 12, 2020 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024